

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

Date:- June 03, 2021

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,

National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G-Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051

Scrip Code: 531599

Mumbai - 400 001

Symbol: FDC

<u>Sub.:</u> <u>Disclosure under Regulation 23(9) of the SEBI Listing Obligations and Disclosure</u> Requirements Regulations, 2015.

Dear Sir / Madam,

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements), 2015. Please find enclosed herewith the Disclosure of Related Party Transactions on a consolidated basis for the half year ended March 31, 2021.

Kindly take the same on record.

Thanking you,

Yours truly,

For FDC LIMITED



Varsharani Katre Company Secretary F-8948

Console Related party disclosures, as required by Ind AS 24 - "Related Party Disclosures" are given below:

Names of related parties where control exists irrespective of whether transactions have occurred or not:

Subsidiary Company

*Fair Deal Corporation Pharmaceuticals SA (Pty) Ltd. (w.e.f 27th July, 2020)

*Previously held as Joint venture.

Names of other related parties with whom transactions have taken place during the year:

Managerial Personnel

- Mr. Mohan A. Chandavarkar Managing Director

- Mr. Ashok A. Chandavarkar Executive Director

- Mr. Nandan M. Chandavarkar Joint Managing Director

- Mr. Ameya A. Chandavarkar Executive Director and CEO-

International Business

- Ms. Nomita R. Chandavarkar Executive Director

- Ms. Swati S. Mayekar Independent Director

Mr. Uday Kumar Gurkar Chairman and Independent

Director

Mr. Mahesh Bijlani Independent Director

Mr. M. G. Parmeswaran Independent Director

Ms. Usha Chandrashekhar Independent Director

Mr. Sanjay Jain Chief Financial Officer

Ms. Varsharani Katre Company Secretary



Console Related party disclosures, as required by Ind AS 24 - "Related Party Disclosures" are given below: (Continued)

Relatives of Managerial Personnel

- Ms. Sandhya M. Chandavarkar, wife of Mr. Mohan A. Chandavarkar
- Ms. Mangala A. Chandavarkar, wife of Mr. Ashok A. Chandavarkar
- Ms. Meera R. Chandavarkar, mother of Ms. Nomita R. Chandavarkar
- Ms. Aditi C. Bhanot, daughter of Mr. Ashok A. Chandavarkar

Enterprises owned or significantly influenced by Managerial Personnel or their relatives

- Anand Chandavarkar Foundation
- Leo Advisors Private Limited
- Virgo Advisors Private Limited
- Shree Trust

Post-employment benefit plans:

- FDC Employees Gratuity Fund
- FDC Employees Superannuation Fund



Console Related party disclosures, as required by Ind AS 24 - "Related Party Disclosures" are given below: (Continued)

Nature of transactions:

Rs. in lakhs

	Rs. in lakhs		
		For the year ended	For the year ended
		31st March 2021	31st March 2020
1	Interest income Fair Deal Corporation Pharmaceuticals SA (Pty) Ltd.	11.01	22.94
2	<u>Donation paid</u> Anand Chandavarkar Foundation	20.00	25.00
3	Corporate Social Responsibility Shree Trust	-	425.00
4	Managerial remuneration*		
	Mr. Mohan A. Chandavarkar	340.98	355.86
	Mr. Ashok A. Chandavarkar	186.65	196.75
	Mr. Nandan M. Chandavarkar	263.96	272.34
	Mr. Ameya A. Chandavarkar	176.43	179.91
	Ms. Nomita R. Chandavarkar	74.69	78.61
	Ms. Swati S. Mayekar	3.40	3.55
	Mr. Uday Kumar Gurkar	3.40	3.55
	Mr. Mahesh Bijlani	2.60	2.60
	Mr. M G Parmeswaran	2.60	2.75
	Ms. Usha A. Chandrashekhar	2.60	2.75
	Mr. Sanjay Jain	93.00	84.53
	Ms. Varsharani Katre	27.62	25.90
		1,177.92	1,209.10



Console Related party disclosures, as required by Ind AS 24 - "Related Party Disclosures" are given below: (Continued)

Nature of transactions: (Continued)

Rs. in lakhs

	Rs. in lakhs		
		For the year ended	For the year ended
1		31st March 2021	31st March 2020
5	Dividend on equity shares paid		
	Mr. Nandan M. Chandavarkar	-	42.10
	Mr. Ameya A. Chandavarkar		82.87
	Ms. Nomita R. Chandavarkar	-	43.93
	Ms. Meera R. Chandavarkar	-	264.35
	Ms. Aditi C. Bhanot	-	9.28
	Sandhya Mohan Chandavarkar Trust	-	149.62
	Mohan Anand Chandavarkar Trust	-	147.03
	Leo Advisors Pvt Ltd	-	124.72
	Virgo advisors Pvt Ltd	-	83.15
	Mr.Sanjay Jain	-	0.01
		-	947.06
6	Buyback of Shares		
	Mr. Nandan M. Chandavarkar	260.49	323.66
	Mr. Ameya A. Chandavarkar	512.80	637.15
	Ms. Nomita R. Chandavarkar	271.83	337.75
	Ms. Meera R. Chandavarkar	1,635.75	2,032.43
	Ms. Aditi C. Bhanot	57.40	71.32
	Sandhya Mohan Chandavarkar Trust	925.84	1,150.36
	Mohan Anand Chandavarkar Trust	909.80	1,130.42
	Leo Advisors Pvt Ltd	771.74	958.88
	Virgo advisors Pvt Ltd	514.49	639.26
	Mr. Sanjay Jain	0.17	-
		5,860.30	7,281.33
		,	
7	Loan granted		
	Fair Deal Corporation Pharmaceuticals SA	41.36	48.32
	(Pty) Ltd.		

Note: * Including perquisites, contribution to Provident fund and other funds but excludes gratuity and compensated absences as the provision is computed for the Parent Company as a whole and separate figures are not available.



Console Related party disclosures, as required by Ind AS 24 - "Related Party Disclosures" are given below: (Continued)

Outstanding amount of related parties:

Rs. in lakhs

			Rs. in lakhs
		As at	As at
		31st March 2021	31st March 2020
1	Outstanding balances payable included in Other current Liabilities Fair Deal Corporation Pharmaceuticals SA (Pty) Ltd.*	-	30.02
2	Outstanding balances payable included in Other Financial Liabilities		7
	Mr. Mohan A. Chandavarkar	195.40	217.29
	Mr. Ashok A. Chandavarkar	130.70	144.34
	Mr. Nandan M. Chandavarkar	146.09	163.34
	Mr. Ameya A. Chandavarkar	113.64	126.82
	Ms. Nomita R. Chandavarkar	49.25	54.62
	Ms. Swati S. Mayekar	2.00	2.00
	Mr. Uday Kumar Gurkar	2.00	2.00
	Mr. Mahesh Bijlani	2.00	2.00
	Mr. M G Parmeswaran	2.00	2.00
	Ms. Usha A. Chandrashekhar	2.00	2.00
	Mr. Sanjay Jain	4.66	3.67
	Ms. Varsharani Katre	1.65	1.53
		651.39	721.61

Terms and conditions of transactions with related parties

The sales to related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and interest free and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

*Fair Deal Corporation Pharmaceuticals SA (Pty) Ltd. became subsidiary company w.e.f 27th July, 2020 and accordingly all inter- group transactions are eliminated on consolidation.

